Qingdao Wanming Cyber Biopharmaceutical

Qingdao Wanming Cyber Biopharmaceutical is a Chinese biotechnology company focused on the development of long-acting recombinant protein and peptide therapeutics. The company leverages its proprietary "Cyber" site-specific PEGylation technology platform to significantly extend the half-life and improve the safety profiles of established biologic drugs. Its lead candidate, WM-101, is a long-acting human growth hormone currently in Phase 3 clinical trials for pediatric growth hormone deficiency. The company's pipeline also includes long-acting versions of erythropoietin and GLP-1 receptor agonists targeting hematologic and metabolic disorders. Headquartered in the Qingdao High-tech Zone, the firm aims to reduce dosing frequency and improve patient compliance for chronic conditions.